Brokerages Anticipate Evolent Health, Inc (EVH) to Post -$0.09 EPS

Equities analysts expect Evolent Health, Inc (NYSE:EVH) to post earnings per share (EPS) of ($0.09) for the current quarter, Zacks reports. Nine analysts have made estimates for Evolent Health’s earnings. The lowest EPS estimate is ($0.12) and the highest is ($0.07). Evolent Health posted earnings per share of ($0.11) in the same quarter last year, which would indicate a positive year over year growth rate of 18.2%. The firm is scheduled to announce its next earnings report on Wednesday, November 8th.

On average, analysts expect that Evolent Health will report full-year earnings of ($0.40) per share for the current year, with EPS estimates ranging from ($0.48) to ($0.36). For the next fiscal year, analysts forecast that the company will report earnings of ($0.02) per share, with EPS estimates ranging from ($0.22) to $0.15. Zacks’ earnings per share averages are an average based on a survey of research analysts that follow Evolent Health.

Evolent Health (NYSE:EVH) last issued its earnings results on Monday, August 7th. The technology company reported ($0.13) EPS for the quarter, meeting analysts’ consensus estimates of ($0.13). Evolent Health had a negative return on equity of 6.44% and a negative net margin of 17.57%. The business had revenue of $107.30 million during the quarter, compared to analyst estimates of $104.45 million. During the same period in the previous year, the company posted ($0.20) EPS. The firm’s revenue was up 89.9% compared to the same quarter last year.

A number of equities analysts recently issued reports on EVH shares. Leerink Swann reissued an “outperform” rating and issued a $32.00 price target (up from $30.00) on shares of Evolent Health in a research note on Monday, June 19th. Cowen and Company reaffirmed an “outperform” rating and set a $35.00 target price on shares of Evolent Health in a research note on Wednesday, June 28th. BidaskClub raised shares of Evolent Health from a “buy” rating to a “strong-buy” rating in a research note on Thursday, July 13th. ValuEngine downgraded shares of Evolent Health from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Finally, Robert W. Baird set a $35.00 price target on shares of Evolent Health and gave the company a “buy” rating in a research report on Tuesday, August 8th. Two analysts have rated the stock with a sell rating, one has issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Evolent Health presently has an average rating of “Buy” and a consensus price target of $28.45.

Shares of Evolent Health (NYSE:EVH) traded down 1.21% during mid-day trading on Monday, reaching $16.30. The company had a trading volume of 389,979 shares. The firm has a 50-day moving average of $17.30 and a 200-day moving average of $17.30. Evolent Health has a 12-month low of $14.50 and a 12-month high of $27.50. The company’s market capitalization is $1.07 billion.

In other Evolent Health news, COO Thomas Peterson III sold 40,540 shares of Evolent Health stock in a transaction on Monday, July 24th. The shares were sold at an average price of $26.00, for a total value of $1,054,040.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Frank J. Williams sold 16,300 shares of Evolent Health stock in a transaction on Thursday, August 3rd. The shares were sold at an average price of $23.73, for a total transaction of $386,799.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 62,840 shares of company stock worth $1,588,679. 8.79% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in EVH. Teachers Advisors LLC increased its holdings in shares of Evolent Health by 5.1% in the 4th quarter. Teachers Advisors LLC now owns 25,119 shares of the technology company’s stock worth $372,000 after buying an additional 1,211 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of Evolent Health by 475.1% during the 1st quarter. Wells Fargo & Company MN now owns 91,658 shares of the technology company’s stock worth $2,044,000 after purchasing an additional 75,720 shares during the period. First Trust Advisors LP purchased a new position in shares of Evolent Health during the 1st quarter worth about $735,000. US Bancorp DE boosted its stake in shares of Evolent Health by 0.3% during the 1st quarter. US Bancorp DE now owns 5,654 shares of the technology company’s stock worth $126,000 after purchasing an additional 19 shares during the period. Finally, Swiss National Bank boosted its stake in shares of Evolent Health by 51.7% during the 1st quarter. Swiss National Bank now owns 61,000 shares of the technology company’s stock worth $1,360,000 after purchasing an additional 20,800 shares during the period. Institutional investors own 82.51% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://ledgergazette.com/2017/10/16/brokerages-anticipate-evolent-health-inc-evh-to-post-0-09-eps.html.

Evolent Health Company Profile

Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.

Get a free copy of the Zacks research report on Evolent Health (EVH)<

On average, analysts expect that Evolent Health will report full-year earnings of ($0.40) per share for the current year, with EPS estimates ranging from ($0.48) to ($0.36). For the next fiscal year, analysts forecast that the company will report earnings of ($0.02) per share, with EPS estimates ranging from ($0.22) to $0.15. Zacks’ earnings per share averages are an average based on a survey of research analysts that follow Evolent Health.

Evolent Health (NYSE:EVH) last issued its earnings results on Monday, August 7th. The technology company reported ($0.13) EPS for the quarter, meeting analysts’ consensus estimates of ($0.13). Evolent Health had a negative return on equity of 6.44% and a negative net margin of 17.57%. The business had revenue of $107.30 million during the quarter, compared to analyst estimates of $104.45 million. During the same period in the previous year, the company posted ($0.20) EPS. The firm’s revenue was up 89.9% compared to the same quarter last year.

A number of equities analysts recently issued reports on EVH shares. Leerink Swann reissued an “outperform” rating and issued a $32.00 price target (up from $30.00) on shares of Evolent Health in a research note on Monday, June 19th. Cowen and Company reaffirmed an “outperform” rating and set a $35.00 target price on shares of Evolent Health in a research note on Wednesday, June 28th. BidaskClub raised shares of Evolent Health from a “buy” rating to a “strong-buy” rating in a research note on Thursday, July 13th. ValuEngine downgraded shares of Evolent Health from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Finally, Robert W. Baird set a $35.00 price target on shares of Evolent Health and gave the company a “buy” rating in a research report on Tuesday, August 8th. Two analysts have rated the stock with a sell rating, one has issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Evolent Health presently has an average rating of “Buy” and a consensus price target of $28.45.

Shares of Evolent Health (NYSE:EVH) traded down 1.21% during mid-day trading on Monday, reaching $16.30. The company had a trading volume of 389,979 shares. The firm has a 50-day moving average of $17.30 and a 200-day moving average of $17.30. Evolent Health has a 12-month low of $14.50 and a 12-month high of $27.50. The company’s market capitalization is $1.07 billion.

In other Evolent Health news, COO Thomas Peterson III sold 40,540 shares of Evolent Health stock in a transaction on Monday, July 24th. The shares were sold at an average price of $26.00, for a total value of $1,054,040.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Frank J. Williams sold 16,300 shares of Evolent Health stock in a transaction on Thursday, August 3rd. The shares were sold at an average price of $23.73, for a total transaction of $386,799.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 62,840 shares of company stock worth $1,588,679. 8.79% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in EVH. Teachers Advisors LLC increased its holdings in shares of Evolent Health by 5.1% in the 4th quarter. Teachers Advisors LLC now owns 25,119 shares of the technology company’s stock worth $372,000 after buying an additional 1,211 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of Evolent Health by 475.1% during the 1st quarter. Wells Fargo & Company MN now owns 91,658 shares of the technology company’s stock worth $2,044,000 after purchasing an additional 75,720 shares during the period. First Trust Advisors LP purchased a new position in shares of Evolent Health during the 1st quarter worth about $735,000. US Bancorp DE boosted its stake in shares of Evolent Health by 0.3% during the 1st quarter. US Bancorp DE now owns 5,654 shares of the technology company’s stock worth $126,000 after purchasing an additional 19 shares during the period. Finally, Swiss National Bank boosted its stake in shares of Evolent Health by 51.7% during the 1st quarter. Swiss National Bank now owns 61,000 shares of the technology company’s stock worth $1,360,000 after purchasing an additional 20,800 shares during the period. Institutional investors own 82.51% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://ledgergazette.com/2017/10/16/brokerages-anticipate-evolent-health-inc-evh-to-post-0-09-eps.html.

Evolent Health Company Profile

Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.

Get a free copy of the Zacks research report on Evolent Health (EVH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply